BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic or Locally-advanced Unresectable Breast Cancer
Interventions: DRUG: BYL719|DRUG: Letrozole|DRUG: Exemestane
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Novartis Pharmaceuticals